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http://www.biomedcentral.com/1471-2407/14/224RESEARCH ARTICLE Open AccessThe cost of lost productivity due to premature
cancer-related mortality: an economic measure
of the cancer burden
Paul A Hanly1* and Linda Sharp2Abstract
Background: Most measures of the cancer burden take a public health perspective. Cancer also has a significant
economic impact on society. To assess this economic burden, we estimated years of potential productive life lost
(YPPLL) and costs of lost productivity due to premature cancer-related mortality in Ireland.
Methods: All cancers combined and the 10 sites accounting for most deaths in men and in women were considered.
To compute YPPLL, deaths in 5-year age-bands between 15 and 64 years were multiplied by average working-life
expectancy. Valuation of costs, using the human capital approach, involved multiplying YPPLL by age-and-gender
specific gross wages, and adjusting for unemployment and workforce participation. Sensitivity analyses were conducted
around retirement age and wage growth, labour force participation, employment and discount rates, and to explore the
impact of including household production and caring costs. Costs were expressed in €2009.
Results: Total YPPLL was lower in men than women (men = 10,873; women = 12,119). Premature cancer-related
mortality costs were higher in men (men: total cost = €332 million, cost/death = €290,172, cost/YPPLL = €30,558;
women: total cost = €177 million, cost/death = €159,959, cost/YPPLL = €14,628). Lung cancer had the highest premature
mortality cost (€84.0 million; 16.5% of total costs), followed by cancers of the colorectum (€49.6 million; 9.7%), breast
(€49.4 million; 9.7%) and brain & CNS (€42.4 million: 8.3%). The total economic cost of premature cancer-related mortality
in Ireland amounted to €509.5 million or 0.3% of gross domestic product. An increase of one year in the retirement age
increased the total all-cancer premature mortality cost by 9.9% for men and 5.9% for women. The inclusion of household
production and caring costs increased the total cost to €945.7 million.
Conclusion: Lost productivity costs due to cancer-related premature mortality are significant. The higher premature
mortality cost in males than females reflects higher wages and rates of workforce participation. Productivity costs
provide an alternative perspective on the cancer burden on society and may inform cancer control policy decisions.
Keywords: Productivity costs, Years of life lost, Cancer, Economic burden, IrelandBackground
Cancer is currently the leading cause of death in eco-
nomically developed countries [1]. While advances in
diagnosis and treatment over the past decades have re-
sulted in improved survival rates in developed countries
[2], future growth in new cancer cases is projected due
to population growth and ageing [1].
To inform the setting of priorities for cancer control it
is necessary to quantify the cancer burden. A variety of* Correspondence: paul.hanly@ncirl.ie
1National College of Ireland, Mayor Street, Dublin 1, Ireland
Full list of author information is available at the end of the article
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article, unless otherwise stated.different metrics are available. One measure that has
gained prominence recently is years of potential life lost
due to premature cancer-related mortality [3]. While
years of potential life lost – and other conventional mea-
sures such as numbers of incident cases and deaths, and
age-standardised rates – are important indicators, they
take an entirely public health perspective, focussing on
the health-related impact or burden of cancer on society.
Cancer also has an economic impact on society [4]. One
important element of this economic impact is the cost
of lost productivity due to cancer-related premature
mortality.tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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ivity, but these have generally considered individual can-
cer sites (e.g. skin [5], breast [6], pancreas [7]). While
providing a useful insight into the proportion of eco-
nomic costs related to individual cancers, they fail to
yield an estimate of the overall burden of cancer-related
premature mortality on the economy. Also, cancer con-
trol initiatives are often site-specific so estimates of
productivity losses associated with different cancers are
needed to inform decisions about allocation of healthcare
funding between initiatives. A very limited number of
studies of productivity loss in multiple cancer sites exist,
mainly from North America [8,9] and Asia [10]; estimates
from Ireland are absent and those from European coun-
tries generally are limited.
The aim of this study was to estimate – for all cancers
and the ten most common causes of cancer death in
males and females – years of potential productive life
lost (YPPLL) and premature mortality costs in Ireland.
We also compare these indicators with numbers of
deaths and age-standardised rates, to illustrate how each
provides a different perspective of the cancer burden on
society.
Methods
General approach
We used the human capital approach to estimate the
value of productivity lost due to cancer-related prema-
ture mortality in Ireland. The human capital approach
measures the value to society of potential productivity,
in the form of output that is lost due to disease-related
morbidity and mortality and is valued by the market
wage. Specifically, we estimated YPPLL, separately for
males and females, for all cancers combined and for
each of the ten most common causes of cancer-related
death in adults. YPPLL were then valued using wage rates
as an approximation of foregone productivity as is usual
in the human capital approach [11]. Since these estimates
relate to lost time from market (i.e. employment-related)
activities, in a scenario analysis, we also estimated costs
for lost time from non-market activities such as house-
hold activities and caring, and valued these using the
proxy good approach which applies the value for an
equivalent service provided in the market to the non-
market activity [12]. Costs are expressed in 2009 euros.
Data sources
Numbers of deaths during 2005-2009 by 5-year age-
group and sex between the ages of 15 and 64 were ab-
stracted from the World Health Organization (WHO)
Cancer Mortality Database for all cancers (International
Classification of Diseases (ICD) 10 00-97, B21). Ethical
approval was not required as the study was based on
publically available data [13] on numbers of deaths fromcancer in Ireland. Data was abstracted on the following
sites: oesophagus (ICD10 15, males and females); stom-
ach (C16, males and females); colorectal (C18-21, males
and females); pancreas (C25, males and females); lung
(C33-34, males and females); breast (C50, females);
uterus (C53-55, females); ovary (C56 – females); prostate
(C61, males); bladder (C67, males); brain & CNS (C70-72,
males and females); non-Hodgkin’s lymphoma (C82-85,
C96, males and females); and leukaemia (C91-95, males
and females). Data on age- and gender-specific wages came
from the National Employment Survey 2009 [14] and data
on age and sex-specific unemployment and labour force
participation rates were abstracted from the Quarterly
National Household Survey [15]. Future wage growth was
approximated by forecast gross domestic product (GDP)
growth for Ireland [16].
As regards non-market activities, time spent on house-
hold activities and caregiving amongst the general popu-
lation were sourced from an Irish time-use survey [17];
this required the assumption that the time spent on
these tasks was the same among people with cancer as
the general population. Wages for household activity
and caregiving were derived from Hanly et al. [12].
Estimation methods
Numbers of deaths were converted into rates using
population estimates from the Central Statistics Office,
and standardised using the World Standard Population
to provide World Age Standardised Rates (WASR; http://
www-dep.iarc.fr/WHOdb/glossary.htm).
Estimation of YPPLL followed a methodology previ-
ously described [18]. To calculate YPPLL we disregarded
any deaths, in children (<15) and beyond 64 years, thereby
assuming all those working will retire at 65, the official
pensionable age in Ireland in 2009. We assumed, for
example, each death in the 55-59 age group was aged
57.5 at death; YPPLL for that death was therefore 7.5 years
(65-57.5). Then, YPPLL for each death were summed
across age-groups, by sex, and by cancer site.
Valuation of premature mortality costs involved multi-
plying, for each death, YPPLL by age- and gender-stratified
gross wages from age of death until 64 (Additional file 1).
Estimates were adjusted for unemployment and labour
force participation rates. For example, a 40 year old female
in 2009 had a 0.69 probability of participating in the work
force and a 0.93 probability of being employed if partici-
pating. These probabilities were applied to her assumed
annual wage rate of €37,140 in 2009 (i.e. (37,140*0.69)
*0.93)). The effect of age on wages as individuals transi-
tion to different wage categories based on hypothetical
age progression was accounted for, as was labour force
participation and employment progression. Wage growth
was calculated at 2.6% per annum [16] and a discount
rate of 4% annually was applied [19]. Cost estimates were
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group to yield age group totals and across age groups to
provide totals for all cancers combined and each cancer
site. Premature mortality costs were also expressed per
cancer death and per YPPLL.
In calculating the value of lost production from non-
market activities, household activity was valued at €15.36
per hour and caregiving activity at €16.82 per hour. Time
spent on each activity was multiplied by these wage rates,
aggregated to an annual cost and summed over working
life expectancy.
Sensitivity analyses
We investigated the sensitivity of the base-case estimates
to variations in several parameters. The wage growth
rate was varied to 1.5% and 3.5% to account for uncer-
tainty over future growth in the Irish economy. The dis-
count rate was varied to 2% and 6%. More up-to-dateTable 1 Average annual number of deaths, WASRs and YPPLL
all cancers, in Ireland (2005 - 2009)
ICD10 Cancer site All deaths % of the total
Male
C00-97,B21 All cancers 4,276 -
Top 10 cancers 3,272 76.5
C15 Oesophagus 218 5.1
C16 Stomach 207 4.8
C18-21 Colorectal 554 13.0
C25 Pancreas 217 5.1
C33-34 Lung 994 23.4
C61 Prostate 530 12.4
C67 Bladder 121 2.8
C70-72 Brain & CNS 150 3.5
C82-85,C96 Non-Hodgkin’s lymphoma 132 3.1
C91-95 Leukaemia 150 3.5
Fema
C00-97, B21 All cancers 3,791 -
Top 10 cancers 2,860 75.4
C15 Oesophagus 118 3.1
C16 Stomach 130 3.4
C18-21 Colorectal 401 10.6
C25 Pancreas 218 5.8
C33-34 Lung 668 17.6
C50 Breast 679 17.9
C53-55 Uterus 172 4.5
C56 Ovary 254 6.7
C70-72 Brain & CNS 109 2.9
C82-85,C96 Non-Hodgkin’s lymphoma 111 2.9
Bold refer to the sum aggregated totals for ‘all cancers’ and the ‘top 10 cancers’ ranestimates of labour force participation rates and employ-
ment rates were used to account for changing labour
market conditions [15]. In addition the effect of extend-
ing the retirement age from 65 to 66 was explored, to
account for a change (to be implemented in 2014) in the
official pension age in Ireland.
Results
Total deaths, world age-standardised mortality rates
(WASRs) and YPPLL by gender
Table 1 presents the number of deaths in people of all
ages, WASRs and YPPLL for all cancers and by site, for
males and females. The top 10 ranked cancers accounted
for 77% of this total in males and 75% in females. Lung
cancer was the most common cause of cancer-related
death in males; breast cancer in females. WASR rank-
ings by cancer site were relatively consistent with these
rankings.for the 10 most common male and female cancers, and
WASR per 100,000 % of the total YPPLL % of the total
s
140.0 - 10,873 -
- - 7,453 68.5
7.4 5.3 598 5.5
6.8 4.9 550 5.1
17.9 12.8 1,211 11.1
7.4 5.3 603 5.5
33.0 23.6 2,089 19.2
15.6 11.1 207 1.9
3.7 12.6 151 1.4
5.6 74.0 1,027 9.4
4.4 3.1 520 4.8
5.0 3.6 499 4.6
les
104.1 - 12,119 -
- - 9,595 79.2
2.8 2.7 178 1.5
3.3 3.2 334 2.8
10.0 9.6 856 7.1
5.5 5.3 361 3.0
18.6 17.9 1,542 12.7
20.5 19.7 3,329 27.5
5.5 5.3 1,126 9.3
7.7 7.4 901 7.4
3.6 3.5 683 5.6
2.8 2.7 288 2.4
ked in Ireland by mortality.
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lower for males than females (10,873 vs 12,119). For
some cancers, their YPPLL ranking differed from their
rankings according to numbers of deaths. For example,
in males, brain & CNS cancers ranked 7th in terms of
deaths and 3rd in YPPLL while prostate ranked 3rd in
deaths and 9th for YPPLL.
Base-case analyses: total premature mortality costs,
overall and by gender
Together, in the base-case analysis, all cancer sites gen-
erated a total of €509.5 million in premature mortality
costs in 2009 (Table 2). In both sexes combined, lung
cancer accounted for 16.5% (€84.0 million) of overall
costs (Figure 1). This was followed by colorectal can-
cer (9.7%; €49.6 million), female breast cancer (€49.4
million; 9.7%) and cancers of the brain & CNS (€42.4
million; 8.3%).Table 2 Premature mortality costs (€, 2009) for the 10 most com
ICD10 Cancer site Total premature
mortality cost
Male
C00-97,B21 All cancers 332,246,992
Top 10 cancers 228,125,322
C15 Oesophagus 18,564,734
C16 Stomach 17,294,647
C18-21 Colorectal 37,253,268
C25 Pancreas 18,624,081
C33-34 Lung 62,927,480
C61 Prostate 5,950,929
C67 Bladder 4,637,827
C70-72 Brain & CNS 32,011,173
C82-85,C96 Non-Hodgkin’s lymphoma 16,113,046
C91-95 Leukaemia 14,748,138
Fema
C00-97,B21 All cancers 177,266,357
Top 10 cancers 139,871,322
C15 Oesophagus 2,442,679
C16 Stomach 4,985,032
C18-21 Colorectal 12,393,845
C25 Pancreas 4,847,345
C33-34 Lung 21,099,185
C61 Breast 49,395,514
C67 Uterus 17,291,434
C70-72 Ovary 12,862,247
C82-85,C96 Brain & CNS 10,370,158
C91-95 Non-Hodgkin’s lymphoma 4,183,884
Bold refer to the sum aggregated totals for ‘all cancers’ and the ‘top 10 cancers’ ranThe total all cancers premature mortality cost was 1.9
times higher in males than females (€332.2 million vs
€177.3 million; Table 2). Lung cancer was the most ex-
pensive male cancer costing €62.9 million (19% of total
male cancer costs). The most expensive female cancer
was breast (€49.4 million; 28% of total female costs).
Premature mortality cost per death and per YPPLL
The average male premature mortality costs per cancer
death was 81% higher than the equivalent female cost
(€290,172 vs €159,959; Table 2). Among the top 10 sites,
in males, the most costly cancer per death was leukae-
mia (€426,247 per death); prostate cancer was the least
costly (€154,169). The highest female cost per death was
for cancer of the uterus (€208,331) and the lowest for
pancreatic cancer (€105,377).
In males, for all cancers combined, the cost per
YPPLL was €30,558, 109% higher than the equivalentmon male and female cancers, and all cancers, in Ireland
% of the total Premature mortality
cost per death
Premature mortality
cost per YPPLL
s
- 290,172 30,558
68.7 276,918 31,381
5.6 268,276 31,045
5.2 315,596 31,445
11.2 276,770 30,775
5.6 263,797 30,911
18.9 220,953 30,123
1.8 154,169 28,818
1.4 246,693 30,714
9.6 421,200 32,367
4.8 385,480 36,579
4.4 426,247 34,100
les
- 159,959 14,628
78.9 155,275 14,578
1.4 118,577 13,762
2.8 178,037 14,925
7.0 147,195 14,487
2.7 105,377 13,428
11.9 114,919 13,683
27.9 172,350 14,840
9.8 208,331 15,363
7.3 141,343 14,283
5.9 202,542 15,183
2.4 157,289 14,553
ked in Ireland by mortality.
Figure 1 Percentage and value of total premature mortality costs (€, 2009) for male and female cancers combined.
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between €28,818 (prostate) and €36,579 (Non-Hodgkin’s
lymphoma) and female costs ranged between €13,428
(pancreas) and €15,363 (uterus).
Gender distribution of YPPLL and premature mortality
costs by age
Figures 2a and b show, by sex, the distribution of YPPLL
and premature mortality costs for all cancers combined
by 5-year age-group. While YPPLL were higher in fe-
males than males between 30 and 49 years, premature
mortality costs for males exceeded those for females
across all age groups with the differential between the
sexes increasing with age after 45.
Sensitivity analysis
Table 3 presents the results of the sensitivity analysis.
Varying the discount rate had the greatest impact on the
estimate of all-cancer premature mortality costs. With a
lower discount rate, the total cost was 15-16% higher in
both sexes; with a higher rate, it was 12% lower. An as-
sumption of lower wage growth resulted in a 7-8% lower
cost in both sexes, and higher growth in a 6-7% higher
cost. Accounting for recent labour market conditions
had a greater impact on male costs (+11%) than female
costs (+1%). An extension of the retirement age by 1 year
to 66 resulted in increased costs by 10% in males and
6% in females.
Scenario analysis: Lost household production and caring
activity
For all cancers, the total cost of lost household produc-
tion and caring activities was €107.6 m for males and€328.7 m for females (Table 4). Male costs were €68.1 m
for lost household production and €39.4 m for lost
caregiving; female costs were €163.6 m and €165.1 m
respectively. In females, the most costly site in terms
of non-market activities was breast cancer (household
production: €45.2 m; caregiving: €45.6 m). In males it was
lung cancer (household production: €13.5 m; caregiving
€7.8 m).
Discussion
Cancer burden: the value of a range of perspectives
Premature mortality costs provide a different perspective
of the cancer burden on society. They provide informa-
tion that complements other more conventional indica-
tors such as numbers of deaths or WASRs. For example,
according to WASRs the all-sites cancer burden is some-
what higher in males than females (WASR M:F = 1.13).
When YPPLL are considered the overall burden is some-
what lower in males (M:F = 0.89), due to the slightly
older age distribution of deaths in males than females
under 65. However, when considering premature mortal-
ity costs from lost market activities a different picture
emerges: male productivity costs dwarf female costs
(€332.2 million vs €177.3 million; M:F = 1.87). This is
due to the incorporation of economic information such
as labour force participation and wage rates into the esti-
mates which tend to inflate male costs relative to female
costs. For instance, the average male workforce partici-
pation rate in 2009 between 15 and 64 years was 77%
compared to 60% for females, and the average male wage
was €44,831 compared to €32,021 for females.
The calculation of premature mortality costs also re-
vealed a new perspective on the relative importance of
Figure 2 YPPLL and total premature mortality costs results by age. (a): Percentage of total YPPLL in males and females1, by age-group, for
all cancers. 1The figures below the bars are the number of YPPLL in males and females in each age-group. (b): Percentage of total premature
mortality costs in males and females1, by age-group, for all cancers. 1The figures below the bars are the premature mortality costs (€2009) in
males and females in each age-group.
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example, brain & CNS cancers emerged as a more im-
portant component of the cancer burden when prema-
ture mortality costs per death were considered (ranking
2nd for males and 2nd for females) rather than numbers
of deaths (ranking 7th and 10th). In contrast, prostate can-
cer dropped from 3rd in terms of numbers of deaths to 9th
in terms of total premature mortality costs. These changes
are driven by the difference between the distribution ofthe ages of death for individual cancers and the age of re-
tirement: this is discussed further below.
Economy-level premature mortality cost burden
The estimated premature cancer-related mortality prod-
uctivity costs were substantial - €332.2 million for males
and €177.3 million for females in 2009, resulting in a
total annual cancer burden of over half a billion euros
for Ireland. The limited previous literature in this area,
Table 3 Sensitivity analyses for all site cancer premature mortality costs (€, 2009) according to different assumptions
for the discount rate, wage growth, labour market characteristics and the retirement age
Male Female
Total premature
mortality cost
% change
from BC
Premature
mortality cost
per death
Total premature
mortality cost
% change
from BC
Premature
mortality cost
per death
BC 332,246,992 - 290,172 177,266,357 - 159,959
Wage growth (BC: 2.6%)
1.50% 307,469,158 (-7.5) 268,532 164,171,979 (-7.4) 148,143
3.50% 353,158,857 (+6.3) 308,436 189,439,743 (+6.9) 170,944
Discount rate (BC: 4%)
2% 384,579,486 (+15.8) 335,877 206,654,039 (+16.6) 186,477
6% 291,598,265 (-12.2) 254,671 155,339,730 (-12.4) 140,173
Labour force participation & unemployment
(BC: 2009 rates)
2013 rates 368,598,902 (+10.9) 321,920 178,709,602 (+0.8) 161,261
Retirement age (BC: 65)
Age = 66 365,157,324 (+9.9) 318,915 187,656,321 (+5.9) 169,334
BC: Base-case.
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mortality productivity costs are considerable; represent-
ing approximately 1% of GDP [8]. Our total cost esti-
mate for Ireland amounted to 0.3% of GDP. Our results
also resonate on a cost per death basis. The estimates
(€290,172 per cancer death among males and €159,959
per cancer death among females) are between 4 and 7
times the average wage in Ireland.
In the context of other cancer-related economic costs,
it is worth noting that productivity costs are commonly
reported to be far in excess of the direct medical costs
of cancer treatment [5,7,20]. For example, in this study
the premature mortality cost of colorectal cancer was
€226,906 per death which is almost six times higher than
the average cost of diagnosis, treatment and follow-up for
a case of colorectal cancer in Ireland (€39,607 in 2008)
[21]. Moreover, it is worth bearing in mind that premature
mortality costs are only one element of the total productiv-
ity loss from market activities due to cancer; other ele-
ments include costs relating to absenteeism from work and
reduced work ability due to cancer or its treatment [22].
In recognition of the fact that individuals also engage
in a range of non-market activities, the loss of which
through premature cancer-related mortality also repre-
sents an economic loss to society, we estimated costs of
potential household production and caring activity lost.
These estimates included the time lost by both working
and non-working individuals and thus extended the per-
spective of the base-case analysis. A previous study that
estimated the value of lost household production and
caring activity due to premature mortality across mul-
tiple cancer sites reported a doubling of costs due to the
addition of non-market activity lost to market-activity[8]. Our findings were similar; the all cancer total lost
productivity cost increased from €509.5 m to €945.7 m
when losses from non-market activities were added to
market activities. As would be expected, due to fact that
women generally undertake more household and care-
giving activities than men, the influence of the inclusion
of non-market activities was greater for females than
males. Indeed, following the inclusion of non-market ac-
tivity costs, total female costs surpassed total male costs
overall (€506.0 m v €439.8 m).
International comparison of premature mortality costs
Two studies have estimated the productivity costs asso-
ciated with multiple cancer sites in the US. Applying the
human capital approach, Bradley et al. [8] estimated US
cancer-related productivity costs of $142.4 billion in
2010 with lung, colorectal and female breast cancer ac-
counting for almost half (44%) of all costs. These findings
correspond to the rankings in our study based on the
costs of market activities, although the combined cost of
the three cancer sites in Ireland was somewhat less as a
proportion of the total (36%). This difference is due to a
greater proportion of deaths in Ireland due to breast can-
cer (Ireland: 12.7% vs US: 7.4%) compared to lung cancer
(Ireland: 20.8% vs US: 28.2%) and lower labour force par-
ticipation rates for females in Ireland compared to the US.
In the US, testicular cancer ranked as the most ex-
pensive site ($1,267,803 per cancer death) followed
by Hodgkin’s lymphoma ($544,118) and brain & CNS
($392,853). We did not include testicular cancer and
Hodgkin’s disease since they ranked outside the ten most
common causes of cancer-related death, but did consider
brain & CNS cancers. After accounting for the exchange
Table 4 Non-market - lost household production and
caring activity - premature mortality costs (€, 2009) for
the 10 most common male and female cancers, and all
cancers, in Ireland
ICD10 Cancer site Total lost household
production cost
Total lost
caring cost
Male
C00-97,B21 All cancers 68,119,367 39,440,641
Top 10 cancers 47,031,364 27,230,833
C15 Oesophagus 3,817,270 2,210,173
C16 Stomach 3,459,966 2,003,296
C18-21 Colorectal 7,646,872 4,441,163
C25 Pancreas 3,854,138 2,231,519
C33-34 Lung 13,500,891 7,816,922
C61 Prostate 1,361,957 788,564
C67 Bladder 964,857 558,646
C70-72 Brain & CNS 6,253,721 3,620,861
C82-85,C96 Non-Hodgkin’s
lymphoma
3,186,066 1,844,710
C91-95 Leukaemia 2,962,003 1,714,979
Female
C00-97,B21 All cancers 163,592,354 165,057,650
Top 10 cancers 130,228,532 131,394,989
C15 Oesophagus 2,455,357 2,477,349
C16 Stomach 4,482,568 4,522,718
C18-21 Colorectal 11,646,872 11,751,193
C25 Pancreas 5,044,263 5,089,444
C33-34 Lung 21,421,357 21,613,229
C61 Breast 45,150,884 45,555,300
C67 Uterus 14,988,015 15,122,262
C70-72 Ovary 12,270,087 12,379,990
C82-85,C96 Brain & CNS 8,921,161 9,001,068
C91-95 Non-Hodgkin’s
lymphoma
3,847,969 3,882,435
Bold refer to the sum aggregated totals for ‘all cancers’ and the ‘top 10 cancers’
ranked in Ireland by mortality.
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was somewhat higher in Ireland than the US (€420,160 vs
€296,622). The difference may be due to the truncation
our estimates at 65 years (the retirement age in Ireland),
while the US study included deaths of all ages.
Few other studies are available for comparative pur-
poses. In Korea [10], liver and stomach cancer emerged
as the largest contributors to total cancer-related prema-
ture mortality costs based on a relatively higher number
of deaths from these cancers than in Ireland or the US
(Korea - stomach cancer: 18.7% of total cancer deaths;
liver cancer: 17.7%).
While these comparisons suggests a (modest) degree
of consistency internationally with regard to the prematuremortality cost burden, they equally highlight the import-
ance of estimating costs specific to an individual setting, in
order to account for geographical differences in the pattern
of cancer deaths and labour force dynamics.
Individual cancer sites
While the observation that lung cancer was the most
costly cancer overall in the base-case analyses is unsur-
prising (given its high relative mortality in both genders
in Ireland), the emergence of cancers of the brain &
CNS as the second most expensive in terms of cost per
death in males and females is more interesting. For can-
cers of the brain & CNS, age of diagnosis is relatively
low (median = 57 vs 67 for all cancers) [23] as is survival
(5-year relative survival for cases diagnosed 2003-2007
was less than 20%) [24]: hence more than 40% of deaths
occur in people younger than retirement age. This re-
veals how numbers of deaths, age at diagnosis and sur-
vival all impact on cost per death: in particular, cancers
with earlier age at onset and which have moderate or
poor prognosis, tend to rank more highly in terms of
cost per death.
Other cancers also ranked differently when alternative
metrics were compared. For example, prostate cancer
accounted for 12.4% of all male cancer deaths but was
one of the lower cost cancers both in terms of total cost
and cost per death. This was due to the relatively low
proportion of deaths in men of working-age combined
with high survival (almost 90% 5-year relative survival)
[25]. Indeed, while 37% of men diagnosed with prostate
cancer were under 65 years at diagnosis, only 7% of
deaths from prostate cancer were in this age group [25].
Implications: value of estimates of lost productivity costs
Estimates of the size of the monetary burden associated
with premature mortality due to cancer may assist pol-
icymakers in deciding the allocation of funds among
competing cancer control activities [8]. In particular they
could help form a picture of the reduction in the eco-
nomic burden that may be achieved by implementation
of particular primary, secondary or tertiary prevention
strategies. As previous research has noted failure to in-
clude these costs in decision-making leads to an under-
estimation of societal costs and may lead to welfare
damaging decisions [26]. Estimates of productivity losses
may also be important sources of data for economic
evaluations of specific health technologies. Some lead-
ing expert panels (for example the US Panel on Cost-
Effectiveness in Health and Medicine [27]) and economic
textbooks and advocate a societal perspective for eco-
nomic evaluations but, in reality, relatively few evalu-
ations include productivity costs [26], perhaps due to
a lack of available data (in some instances, at least).
Moreover, combined with direct medical costs and direct
Hanly and Sharp BMC Cancer 2014, 14:224 Page 9 of 10
http://www.biomedcentral.com/1471-2407/14/224non-medical costs (including patient time, travel and out-
of-pocket costs), such estimates provide an important - yet
rarely quantified - building block in constructing an accur-
ate measure of the total economic burden of cancer on
society.
Strengths and limitations
As far as we are aware, this study provides the first esti-
mates of lost productivity costs for multiple cancer sites
for a western European country. Key strengths of the
study include the use of population data and the applica-
tion of a simple and transparent methodology to value
lost productivity. Nevertheless, there are some limita-
tions. Use of the human capital approach to estimate
costs for market activities puts greater weight on older
males who are working compared to younger citizens
(who earn lower wages), especially younger females. For
example a male aged 50 earned €55,967 on average in
2009, whereas a female aged 30 earned €37,549. Never-
theless, the human capital approach is widely used
throughout the economic literature thus enhancing the
comparability of our results. Alternative methodological
techniques including the friction cost approach and the
willingness-to-pay approach are also not without flaws
and limitations [11].
In terms of potential limitations, our estimates for lost
household production and caring activity were based
on reported time use in 2005 in the general population
as no equivalent estimates exist for the cancer popula-
tion. If patterns of time use in cancer patients differ
from those among people without cancer (which they
might well do due to the effects that cancer and its
treatment may have on functional status) our esti-
mates will not reflect the true value of this potential
lost non-market activity. Uncertainty also remains over
the correct valuation method for non-market activity.
While we used the proxy good approach in this study,
other methods exist and these may result in quite differ-
ent estimates [12].
We did not estimate productivity losses due to mor-
bidity; this was due to a lack of reliable site-specific data.
However, most previous studies have found that prema-
ture mortality costs constitute the overwhelming major-
ity of the total productivity cost for market activities
[6,7,28,29]. We focused on the potential productivity
losses to the economy of working individuals between
the ages of 15 and 64: non participants in the labour
force were thus explicitly excluded in the base-case ana-
lysis. The choice of 64 as a cut-off age reflected the offi-
cial pensionable age in Ireland in 2009 beyond which the
majority of individuals retire. While the effective re-
tirement age can be lower (or higher) than the pen-
sionable age, in Ireland the effective retirement age is
64.6 for males and 62.6 for females (http://www.oecd.org/els/public-pensions/ageingandemploymentpolicies-
statisticsonaverageeffectiveageofretirement.htm).
Conclusion
Lost productivity costs due to cancer-related premature
mortality are significant, amounting to over half a billion
euros in Ireland in 2009. Total lost productivity costs
due to market activities were 1.65 times higher in males
than females, due to higher wages and higher rates of
workforce participation. Lung and breast cancer – but
not prostate cancer - were major contributors to the
overall total cost. Cancers with earlier age at onset and
lower survival, ranked more highly as regards cost per
death. Productivity costs provide an alternative perspec-
tive of the cancer burden on society. They give an indi-
cation of the potential cost savings that could accrue
from effective primary prevention, earlier diagnosis and/
or advances in treatments, and may assist policymakers
in determining allocation of funds among competing
health care interventions, especially during times of con-
strained finances.
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